JP2024545496A5 - - Google Patents
Info
- Publication number
- JP2024545496A5 JP2024545496A5 JP2024533948A JP2024533948A JP2024545496A5 JP 2024545496 A5 JP2024545496 A5 JP 2024545496A5 JP 2024533948 A JP2024533948 A JP 2024533948A JP 2024533948 A JP2024533948 A JP 2024533948A JP 2024545496 A5 JP2024545496 A5 JP 2024545496A5
- Authority
- JP
- Japan
- Prior art keywords
- compound
- pharmaceutically acceptable
- acceptable salt
- dose
- pharmaceutical composition
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Pending
Links
Applications Claiming Priority (7)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US202163288377P | 2021-12-10 | 2021-12-10 | |
| US63/288,377 | 2021-12-10 | ||
| US202263421524P | 2022-11-01 | 2022-11-01 | |
| US63/421,524 | 2022-11-01 | ||
| US202263429376P | 2022-12-01 | 2022-12-01 | |
| US63/429,376 | 2022-12-01 | ||
| PCT/US2022/052411 WO2023107697A1 (en) | 2021-12-10 | 2022-12-09 | Methods of administering a modulator of hemoglobin |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2024545496A JP2024545496A (ja) | 2024-12-09 |
| JP2024545496A5 true JP2024545496A5 (enExample) | 2025-10-06 |
Family
ID=85108880
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2024533948A Pending JP2024545496A (ja) | 2021-12-10 | 2022-12-09 | ヘモグロビンのモジュレーターを投与する方法 |
Country Status (10)
| Country | Link |
|---|---|
| US (1) | US20250041312A1 (enExample) |
| EP (1) | EP4444285A1 (enExample) |
| JP (1) | JP2024545496A (enExample) |
| KR (1) | KR20240116826A (enExample) |
| AU (1) | AU2022408097B2 (enExample) |
| CA (1) | CA3241881A1 (enExample) |
| IL (1) | IL312835A (enExample) |
| MX (1) | MX2024007064A (enExample) |
| TW (1) | TW202339732A (enExample) |
| WO (1) | WO2023107697A1 (enExample) |
Families Citing this family (1)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| TW202515579A (zh) * | 2023-06-13 | 2025-04-16 | 美商全球血液治療公司 | 投予血紅素的調節劑之方法 |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US3845770A (en) | 1972-06-05 | 1974-11-05 | Alza Corp | Osmatic dispensing device for releasing beneficial agent |
| US4326525A (en) | 1980-10-14 | 1982-04-27 | Alza Corporation | Osmotic device that improves delivery properties of agent in situ |
| US5364620A (en) | 1983-12-22 | 1994-11-15 | Elan Corporation, Plc | Controlled absorption diltiazem formulation for once daily administration |
| US5023252A (en) | 1985-12-04 | 1991-06-11 | Conrex Pharmaceutical Corporation | Transdermal and trans-membrane delivery of drugs |
| US5001139A (en) | 1987-06-12 | 1991-03-19 | American Cyanamid Company | Enchancers for the transdermal flux of nivadipine |
| US4992445A (en) | 1987-06-12 | 1991-02-12 | American Cyanamid Co. | Transdermal delivery of pharmaceuticals |
| US4902514A (en) | 1988-07-21 | 1990-02-20 | Alza Corporation | Dosage form for administering nilvadipine for treating cardiovascular symptoms |
| HRP20220295T1 (hr) * | 2018-11-19 | 2022-05-13 | Global Blood Therapeutics, Inc. | Spojevi 2-formil-3-hidroksifeniloksimetila koji mogu modulirati hemoglobin |
| CA3219786A1 (en) * | 2021-05-14 | 2022-11-17 | Global Blood Therapeutics, Inc. | Solid forms of a modulator of hemoglobin |
-
2022
- 2022-12-09 US US18/717,181 patent/US20250041312A1/en active Pending
- 2022-12-09 TW TW111147489A patent/TW202339732A/zh unknown
- 2022-12-09 IL IL312835A patent/IL312835A/en unknown
- 2022-12-09 JP JP2024533948A patent/JP2024545496A/ja active Pending
- 2022-12-09 WO PCT/US2022/052411 patent/WO2023107697A1/en not_active Ceased
- 2022-12-09 KR KR1020247023029A patent/KR20240116826A/ko active Pending
- 2022-12-09 EP EP22847662.8A patent/EP4444285A1/en active Pending
- 2022-12-09 AU AU2022408097A patent/AU2022408097B2/en active Active
- 2022-12-09 MX MX2024007064A patent/MX2024007064A/es unknown
- 2022-12-09 CA CA3241881A patent/CA3241881A1/en active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2023002662A5 (enExample) | ||
| TW202202139A (zh) | 以２－〔（４－｛６－〔（４－氰基－２－氟苄基）氧基〕吡啶－２－基｝哌啶－１－基）甲基〕－１－〔（２ｓ）－氧雜環丁烷－２－基甲基〕－１ｈ－苯並咪唑－６－甲酸或其藥學上的鹽治療第２型糖尿病或肥胖症或體重過重 | |
| US20240197692A1 (en) | Combination Comprising Everolimus and Amcenestrant | |
| JP2023535744A5 (enExample) | ||
| JP2018537507A (ja) | 加齢に関連する認知障害及び神経炎症を予防及び／又は治療する方法 | |
| JP2016518403A (ja) | トレハロースの非経口投与によるタンパク質凝集ミオパシーおよび神経変性疾患の治療 | |
| JP2023548429A5 (enExample) | ||
| JP2024531188A5 (enExample) | ||
| EP4494701A3 (en) | New therapeutic combinations for the treatment of progressive fibrosing interstitial lung diseases | |
| JP2024545496A5 (enExample) | ||
| JP2023553253A5 (enExample) | ||
| US20160287535A1 (en) | Uses and Methods for the Treatment of Liver Diseases or Conditions | |
| US11628163B2 (en) | 1-piperidinepropionic acid for treating a fibrosing disease | |
| JP2022058873A5 (enExample) | ||
| US11413260B2 (en) | Use of 1,3-propanedisulfonic acid or pharmaceutically acceptable salts thereof for the treatment of sarcoidosis | |
| JP6454436B1 (ja) | ペマフィブラートを含有する医薬 | |
| JP2021138710A5 (enExample) | ||
| WO2024139978A1 (zh) | Vofopitant用于治疗肺纤维化的用途 | |
| KR20200014880A (ko) | 테세탁셀 및 카페시타빈에 대한 투약 일정 | |
| WO2012106947A1 (zh) | 含维生素d和二甲双胍的药物组合物 | |
| US20140296149A1 (en) | Compositions and Methods for the Treatment of Cardiac Surgery-Associated Acute Kidney Injury with Annexin A1 Peptide | |
| JP2024541770A5 (enExample) | ||
| JP6188784B2 (ja) | 炎症性および免疫性疾患の治療のための組成物 | |
| WO2025080252A1 (en) | Methods of use of (4r,5r)-5-(2-chlorophenyl)-4-(5-(phenylethynyl)pyridin-3-yl)oxazolidin-2-one | |
| TWI672145B (zh) | 預防及／或治療代謝疾病的醫藥組合物及其用途 |